From neurotechnology to thrombectomy and remote monitoring, this week’s funding rounds highlight a strong focus on technologies advancing clinical validation and real-world deployment. Read more below.

Beacon Biosignals upsizes Series B to $97M

A syndicate of healthcare and technology investors, including Innoviva, Google Ventures, Nexus NeuroTech Ventures, S32, Catalio Capital Management and Takeda led the initial Series B. General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures participated, too.

New investors JSL Health, Palo Santo VC, Kicker Ventures and Samsung Next contributed to the extension. The company’s cumulative financing now totals more than $132M.

Last week’s tracker: Blackstone, Diagens & more

CEO Jacob Donoghue

E2 raises $80M Series C for Hēlo thrombectomy system

Gilde Healthcare and Norwest co-led the latest financing for the Menlo Park, California-based company. Existing investors, including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, also participated.

Two existing undisclosed strategic investors and a new global strategic investor took part, too. The latest funding supports commercialization efforts for its novel Hēlo thrombectomy platform.

CEO Dan Rose

Route 92 Medical brings in $50M growth financing

New investor Sectoral Asset Management joined lead investor Novo Holdings in the financing. Existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners and the Vertical Group participated, too.

The company plans to use the proceeds from the financing to support its next phase growth.

Founder and CEO Tony Chou

neuroClues closes €10M Series A, bringing total funding to €25M

The investment brings the company’s total funding raised to €25 million and was led by Teampact Ventures, White Fund SA, and the EIC Fund, with continued support from invest.bw, LeanSquare, and Wallonie Entreprendre.

The company’s broader ambition is to shift neurology toward earlier diagnosis and prevention – at a stage when interventions can still make a meaningful difference for patients.

Co-Founder and CEO Antoine Pouppez

Vertigenius raises $3M to advance AI-enabled patient monitoring

Funding was led by Atlantic Bridge with support from Enterprise Ireland, MedTech Syndicate, Ascentifi, IRRUS Investments, Xcendra Ventures and others to accelerate commercialization and US clinic adoption.

The round follows earlier seed funding of roughly $2.1M, bringing total capital raised to more than $5M to date.

CEO Mark Barry